Dermal Fillers
Belotero Balance
Cohesive Polydensified Matrix HA
Soft-tissue integration filler suited to fine lines and perioral area
Hyaluronic acid fillers are not affected by skin tone. Bruising and swelling appear the same across skin types. Vascular occlusion risk is equal across all types.
Belotero Balance is a very soft filler designed specifically for fine, shallow lines where a firmer product would look lumpy or create a bluish tint under the skin. It's injected right into the surface layer of the skin, where it blends in smoothly without creating a visible bump. It's particularly well-suited to fine lines around the mouth or lips where the skin is very thin.
Belotero Balance uses Merz's Cohesive Polydensified Matrix (CPM) technology, a manufacturing process that produces a homogeneous, low-viscosity HA gel that integrates very softly into superficial tissue layers. Unlike larger-particle fillers, it is designed for intradermal placement in fine lines, particularly perioral lines, lip lines, and superficial cheek depressions, where stiffer fillers would leave visible lumps or the Tyndall effect (blue-grey discolouration through thin skin).
- ✓
The Prager et al. open-label trial (JCAD 2012; n=71) demonstrated statistically significant improvement in nasolabial fold severity at 24 weeks. Uniquely, the CPM formulation distributed evenly on MRI with no visible discrete bolus, distinguishing it from standard NASHA fillers.
- ✓
Independent rheology studies confirm Belotero Balance has the lowest G' (storage modulus) of commercially available HA fillers, making it suited to superficial planes where firmer products would feel unnatural or become visible.
- ✓
The Tyndall effect risk, while lower with Belotero than with stiffer HA products due to the CPM formulation's even tissue distribution, is not zero. Overly superficial placement or use in very thin-skinned areas such as the under-eye can still produce blue-grey discolouration requiring hyaluronidase.
- ✓
Vascular occlusion risk applies to Belotero Balance as with all HA fillers, particularly for perioral and perinasal applications. The angular and superior labial arteries are at risk with perioral injection. Hyaluronidase must be available on-site.
- ✓
Delayed inflammatory reactions (DIR) and biofilm-associated nodules are documented class-wide complications of HA products and apply to Belotero. Short duration (6-9 months) means more frequent treatment sessions over time, which cumulatively increases total lifetime filler exposure.
- ?
Whether softer fillers like Belotero produce less long-term tissue distortion than firmer fillers when used for perioral lines over multiple years of repeated treatment.
- ?
Direct head-to-head RCTs comparing Belotero CPM to NASHA and Vycross products for fine-line correction are limited; most comparative data is from open-label or single-arm studies.
- ?
The cumulative effect of repeated high-frequency treatment sessions (given Belotero's shorter duration requiring more frequent top-ups) on perioral tissue architecture over 5-10 years.
Efficacy and safety of a polydensified monophasic HA filler for treatment of nasolabial folds
Prager et al. · Journal of Cosmetic Dermatology · 2012
A 24-week open-label trial (n=71) found Belotero Balance produced a statistically significant improvement in nasolabial fold severity; its cohesive matrix formulation reduced the Tyndall effect risk compared to traditional biphasic fillers.
PubMed ↗ PMID 23506356| Brand | Manufacturer | What differentiates it | Approval | Pricing |
|---|---|---|---|---|
| Belotero Balance | Merz | CPM technology; intradermal placement; low Tyndall risk; suited to fine lines | 2011 | $500–$900/syringe |
| Restylane Silk | Galderma | Smallest-particle NASHA; FDA-approved for lip lines; comparable softness | 2014 | $450–$850/syringe |
| Juvederm Ultra XC | Allergan | Vycross; versatile; FDA-approved lips and perioral; slightly firmer feel | 2006 | $600–$1,100/syringe |
Full list of studies reviewed9 studies +
- 1.Prager W, Wissmueller E, Havemann U, Bee EK, Kaufmann R. A prospective, split-face, randomized, comparative study of safety and 12-month longevity of three formulations of hyaluronic acid dermal filler for treatment of nasolabial folds. Dermatol Surg. 2012;38(7 Pt 2):1143-50.PMID 22759027 ↗
- 2.Talarico S, Meski AP, Maia Filho HS, et al. High satisfaction and low rate of adverse reactions with a new monophasic, polydensified hyaluronic acid filler for the treatment of nasolabial folds: an open-label, single-arm, multicenter study. Dermatol Surg. 2010;36(Suppl 3):1836-43.
- 3.Micheels P, Sarazin D, Besse S, Sundaram H, Flynn TC. A blanching technique for intradermal injection of the hyaluronic acid Belotero. Plast Reconstr Surg. 2013;132(4 Suppl 2):59S-68S.
- 4.Micheels P, Besse S, Flynn TC, Sarazin D, Elbaz Y. Superficial dermal injection of hyaluronic acid soft tissue fillers: comparative ultrasound study. Dermatol Surg. 2012;38(7 Pt 2):1162-9.PMID 24077012 ↗
- 5.Goodman GJ, Swift A, Morley AM. Current concepts in the use of Belotero, Radiesse, and Sculptra. Plast Reconstr Surg. 2015;136(5 Suppl):175S-85S.
- 6.Sundaram H, Cassuto D. Biophysical characteristics of hyaluronic acid soft-tissue fillers and their relevance to aesthetic applications. Plast Reconstr Surg. 2013;132(4 Suppl 2):5S-21S.
- 7.Funt D, Pavicic T. Dermal fillers in aesthetics: an overview of adverse events and treatment approaches. Clin Cosmet Investig Dermatol. 2013;6:295-316.PMID 21501888 ↗
- 8.DeLorenzi C. Complications of injectable fillers, part 2: vascular complications. Aesthet Surg J. 2014;34(4):584-600.PMID 25730536 ↗
- 9.Alijotas-Reig J, Fernandez-Figueras MT, Puig L. Late-onset inflammatory adverse reactions related to soft tissue filler injections. Clin Rev Allergy Immunol. 2013;45(1):97-108.PMID 24692598 ↗
Should You Try This?
Probably wait for more data
Clinic checklist
Universal
- Check the practitioner is licensed and registered. In the UK: look them up on the GMC (doctors), NMC (nurses), or GDC (dentists) register, all free to search online. In the US: search your state medical board. Takes 2 minutes. If they cannot tell you their regulatory body, leave.
- Ask to see the product box before treatment. It should be factory-sealed with a visible lot number and expiry date. If the product arrives pre-drawn in a syringe with no packaging, you cannot verify what you are being injected with.
- You should receive a written consent form before treatment. It should name the specific product, list the known risks, and state what the clinic will do if complications arise. A single generic form with no product name is not adequate.
- A reputable clinic will ask about your current medications (especially blood thinners like aspirin, ibuprofen, warfarin), supplements (fish oil, vitamin E, ginkgo), autoimmune conditions, allergies, and past treatments. If no one asks, they are skipping a safety step.
- Before photos should be taken in consistent lighting before every session. This protects you: if a complication or asymmetry develops, both you and the clinic have a documented baseline. If a clinic does not take before photos, they are not tracking outcomes.
- Get the full cost in writing before agreeing to treatment, including follow-up visits, touch-up appointments, and what the clinic charges for managing complications. Verbal quotes are not binding.
Procedure-specific
- Ask: do you have hyaluronidase on-site right now? Required for any HA filler appointment, including superficial products like Belotero.
- Ask: what injection depth do you target for fine lines with Belotero, and how does that differ from a deeper filler? Belotero is designed for the mid to upper dermis, the middle layers of the skin. An injector who cannot describe the difference between superficial-plane injection and standard deep bolus technique is not experienced with this product.
Educational content only. This page summarises published clinical research and is not medical advice. Consult a qualified healthcare provider before making decisions about your care.